Clinical treatments for ARID1A and SMARCA4 mutant tumors, as well as small molecule inhibitors, are available, but there are still some basic research and clinical treatment-related questions that need to be explored, e.g., can ARID1A mutant breast and ovarian cancer cell lines and high-grade plasmacytoid ovarian cancers, which have a certain degree of resistance to PARP inhibitors, be used in combination with a certain drug to increase their sensitivity? This evidence concerns the gene SMARCA4 and ovarian carcinoma.